<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Philippe</forename><surname>Garot</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Hôpital Claude Galien</orgName>
								<orgName type="institution" key="instit2">Institut Cardiovasculaire Paris-sud Ramsay-Générale de Santé</orgName>
								<orgName type="institution" key="instit3">Quincy Sous-Sénart</orgName>
								<address>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Hôpital Privé Jacques Cartier</orgName>
								<orgName type="institution" key="instit2">Institut Cardiovasculaire Paris-sud Ramsay-Générale de Santé</orgName>
								<address>
									<settlement>Massy</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marie-Claude</forename><surname>Morice</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Hôpital Privé Jacques Cartier</orgName>
								<orgName type="institution" key="instit2">Institut Cardiovasculaire Paris-sud Ramsay-Générale de Santé</orgName>
								<address>
									<settlement>Massy</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Damras</forename><surname>Tresukosol</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Siriraj Hospital</orgName>
								<address>
									<settlement>Bangkok</settlement>
									<country key="TH">Thailand</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PHD</roleName><forename type="first">Stuart</forename><forename type="middle">J</forename><surname>Pocock</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">London School of Hygiene and Tropical Medicine</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS, BSC</roleName><forename type="first">Ian</forename><forename type="middle">T</forename><surname>Meredith</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">MonashHeart and Monash University</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Alexandre</forename><surname>Abizaid</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Instituto Dante Pazzanese de Cardiologia</orgName>
								<address>
									<settlement>São Paulo</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">and Hospital Albert Einstein</orgName>
								<address>
									<settlement>São Paulo</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Didier</forename><surname>Carrié</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Cardiology Department</orgName>
								<orgName type="institution">Toulouse Rangueil Hospital</orgName>
								<address>
									<settlement>Toulouse</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christoph</forename><surname>Naber</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Medical Statistics</orgName>
								<orgName type="institution" key="instit1">Contilia Heart and Vascular Centre</orgName>
								<orgName type="institution" key="instit2">Elisabeth Krankenhaus</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Andres</forename><surname>Iñiguez</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Cardiology Department</orgName>
								<orgName type="institution">Complejo Hospitalario Universitario de Vigo, Hospital Meixoeiro</orgName>
								<address>
									<settlement>Meixoeiro</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Suneel</forename><surname>Talwar</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Dorset Heart Centre</orgName>
								<orgName type="institution">Royal Bournemouth Hospital</orgName>
								<address>
									<settlement>Bournemouth</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Ian</forename><forename type="middle">B A</forename><surname>Menown</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Craigavon Cardiac Center</orgName>
								<address>
									<settlement>Portadown</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Evald</forename><forename type="middle">H</forename><surname>Christiansen</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Aar-hus University Hospital</orgName>
								<address>
									<settlement>Skejby</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PHD</roleName><forename type="first">John</forename><surname>Gregson</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">London School of Hygiene and Tropical Medicine</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PHD</roleName><forename type="first">Samuel</forename><surname>Copt</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Biosensors Europe</orgName>
								<address>
									<settlement>Morges</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Thomas</forename><surname>Hovasse</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Hôpital Privé Jacques Cartier</orgName>
								<orgName type="institution" key="instit2">Institut Cardiovasculaire Paris-sud Ramsay-Générale de Santé</orgName>
								<address>
									<settlement>Massy</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Philipp</forename><surname>Lurz</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Internal Medicine/Car-diology</orgName>
								<orgName type="institution">Universität Leipzig-Herzzentrum</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Luc</forename><surname>Maillard</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Service de Cardiologie</orgName>
								<orgName type="department" key="dep2">Groupement de Coopération Sanitaire Etablissements de Santé</orgName>
								<orgName type="institution">Axium-Rambot</orgName>
								<address>
									<settlement>City</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Florian</forename><surname>Krackhardt</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Campus Virchow Klinikum</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Paul</forename><surname>Ong</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">Tan Tock Seng Hospital</orgName>
								<address>
									<country key="SG">Singapore</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jonathan</forename><surname>Byrne</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">King&apos;s College Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country>United</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Simon</forename><surname>Redwood</surname></persName>
						</author>
						<author>
							<persName><roleName>PHD</roleName><forename type="first">Ute</forename><surname>Windhövel</surname></persName>
						</author>
						<author>
							<persName><roleName>BA</roleName><forename type="first">Samantha</forename><surname>Greene</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Biosensors Europe</orgName>
								<address>
									<settlement>Morges</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hans-Peter</forename><surname>Stoll</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Biosensors Europe</orgName>
								<address>
									<settlement>Morges</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Philip</forename><surname>Urban</surname></persName>
						</author>
						<title level="a" type="main">2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">32939CFF9A70E893BBB65A2DFF8CDCA2</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:13+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>BACKGROUND A 1-year follow-up, polymer-free metallic stent coated with biolimus-A9 followed by 1-month dual antiplatelet therapy is safer and more effective than a bare-metal stent (BMS) for patients with high risk of bleeding.</s></p><p><s>OBJECTIVES This study analyzed 2-year outcomes to determine whether these benefits are maintained.</s></p><p><s>METHODS In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding risk patients to receive a drug-coated stent (DCS) or a BMS followed by 1-month dual antiplatelet therapy.</s><s>The primary safety endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosis.</s><s>The primary efficacy endpoint was clinically driven target lesion revascularization.</s></p><p><s>RESULTS At 2 years, the primary safety endpoint had occurred in 147 DCS and 180 BMS patients (15.3%) (hazard ratio: 0.80; 95% confidence interval: 0.64 to 0.99; p ¼ 0.039).</s><s>Clinically driven target lesion revascularization occurred for 77 DCS and 136 BMS patients (12.0%) (hazard ratio: 0.54; 95% confidence interval: 0.41 to 0.72; p &lt; 0.0001).</s><s>Major bleeding occurred in 8.9% of DCS and 9.2% of BMS patients (p ¼ 0.95), and a coronary thrombotic event (myocardial infarction and/ or stent thrombosis) occurred in 8.2% of DCS and 10.6% of BMS patients (p ¼ 0.045).</s><s>One-year mortality was 27.1% for a major bleed and 26.3% for a thrombotic event.</s><s>At 2 years, multivariate correlates of major bleeding were age &gt;75 years, anemia, raised plasma creatinine, and planned long-term anticoagulation.</s><s>Correlates of the primary safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of stents implanted, and use of a BMS rather than a DCS.</s></p><p><s>CONCLUSIONS Safety and efficacy benefits of DCS over BMS were maintained for 2 years in high bleeding risk patients.</s><s>Rates of major bleeding and coronary thrombotic events were no different and were associated with a substantial and comparable mortality risk.</s><s>(A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE];</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>P atients at high bleeding risk (HBR) who require percutaneous coronary intervention (PCI) are a challenging group who need careful evaluation of both their thrombotic and bleeding risks when selecting a stent and determining duration and intensity of antithrombotic management <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b1">2)</ref>.</s><s>Little evidence exists to aid such decisions, because HBR patients are mostly excluded from clinical trials of antithrombotics and PCI <ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b5">(6)</ref>.</s><s>Until recently, the perceived need for a very short course of dual antiplatelet treatment (DAPT) often led operators to prefer a bare-metal stent (BMS) to a drug-eluting stent (DES) for such patients <ref type="bibr" target="#b6">(7,</ref><ref type="bibr" target="#b7">8)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The LEADERS FREE (A Prospective Randomized</head><p><s>Comparison of the BioFreedom Biolimus A9 Drug Coated Stent versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding) trial recently showed that, together with a 1-month DAPT course, a polymer-free metallic drug-coated stent (DCS) was both safer and more effective than a BMS for patients at high risk of bleeding who were followed for 1 year <ref type="bibr" target="#b0">(1)</ref>.</s><s>This DCS (BioFreedom, Biosensors Interventional Technologies, Singapore) transfers biolimus A9, a highly lipophilic sirolimus analog, into the vessel wall over a 1-month period <ref type="bibr" target="#b8">(9)</ref>.</s><s>This is in contrast to currently available polymer-coated DES, which generally release the drug over a period of several months.</s></p><p><s>Limited encouraging 5-year data are available from the first-in-man evaluation of this DCS for 60 selected patients treated with DAPT for 6 to 12 months <ref type="bibr" target="#b9">(10)</ref>.</s></p><p><s>For HBR patients with 1-month DAPT treatment, further evidence is needed to assess whether the firstyear benefits of DCS over BMS are maintained in the long term.</s><s>Also, because of the unique features of the LEADERS FREE design (i.e., unusual patient population, very short DAPT time) together with the observed high rate of major bleeding in both arms after 1 year (1), it is important to evaluate the balance of the 2-year risks and the baseline and procedure correlates of the primary safety endpoint and of major bleeding events.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>PATIENTS.</s><s>Patient selection and study design of the LEADERS FREE trial have been described previously <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b11">11)</ref>.</s><s>Inclusion required a clinical indication for PCI together with 1 or more HBR criteria: most frequently age 75 or older, planned prolonged oral anticoagulation, renal insufficiency, planned major surgery, anemia or recent transfusion, and cancer.</s><s>Such patients were potential candidates for a BMS instead of a DES, owing to their perceived need for only 1 month of DAPT.</s></p><p><s>STUDY DEVICE AND PROCEDURE.</s><s>The BioFreedom polymer-free biolimus A9 coated stent, the control Gazelle BMS (Biosensors Europe, Morges, Switzerland; and Biosensors Interventional Technologies), and the PCI procedure have been described</s></p><p><s>previously <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b11">11)</ref>.</s><s>A double-blind design was used.</s><s>All  Garot et al.</s></p><formula xml:id="formula_0">J A N U A R Y 1 7 , 2 0 1 7 : 1 6 2 -7 1</formula><p><s>2-Year Outcomes of HBR Patients After Polymer-Free DCS the sponsor.</s><s>The respective roles of the executive committee, the sponsor, Cardiovascular European Research Center, and authors have remained unchanged <ref type="bibr" target="#b0">(1)</ref>.</s><s>The first author, statisticians (J.G., S.C.), and executive committee had unrestricted access to the data and prepared all drafts of the manuscript; they attest to the completeness and accuracy of all data and to the adherence to study protocol.</s><s>The ethics committee at each site approved the trial, and written informed consent was obtained from all patients.</s></p><p><s>STUDY ENDPOINTS.</s><s>The primary safety endpoint was the cumulative incidence of a composite of cardiac death, myocardial infarction, or definite or probable stent thrombosis.</s><s>The primary efficacy endpoint was the incidence of clinically driven target lesion revascularization.</s><s>Pre-specified secondary endpoints included all-cause and cardiac mortality, bleeding (Bleeding Academic Research Consortium</s></p><p><s>[BARC] definitions) <ref type="bibr" target="#b12">(12)</ref>, myocardial infarction (third universal definition) <ref type="bibr" target="#b13">(13)</ref>, stent thrombosis (Academic Research Consortium definitions) <ref type="bibr" target="#b14">(14)</ref>, and types of coronary revascularization.</s><s>A clinical events committee adjudicated all components of the primary endpoints and all bleeding events, according to predefined criteria <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b11">11)</ref>.</s><s>STATISTICAL ANALYSIS.</s><s>All results are based on a modified intention-to-treat analysis after exclusion of 34 patients who had no suitable lesion for PCI <ref type="bibr" target="#b0">(1)</ref>.</s></p><p><s>Continuous variables are presented as means, and categorical data as counts and percentages.</s><s>Time-toevent analyses were performed using Kaplan-Meier plots, log-rank tests, and proportional-hazard models to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs).</s><s>Proportional hazard assumptions were checked using Schoenfeld residuals.</s><s>Patients were censored at death, withdrawal from study, scheduled end of study, or 730 days postrandomization, whichever occurred first.</s><s>We performed sensitivity analyses using the Fine and Gray method to estimate cumulative incidence of events while adjusting for the competing risk of mortality <ref type="bibr" target="#b15">(15)</ref>.</s></p><p><s>For major bleeding we used the BARC 3, 4, or 5 bleeding definition.</s><s>To explore covariates associated with major bleeding and the primary safety endpoint, we performed multivariate analyses investigating the potential influence of 32 baseline and procedural variables (Online Table <ref type="table" target="#tab_1">1</ref>) by means of proportional hazard models.</s><s>We selected a final model for each outcome by using forward stepwise variable selection on data with complete information on all covariates and an inclusion criterion of p &lt; 0.01.</s><s>Based on the trial results, we forced inclusion of BMS in the model for the primary safety endpoint.</s><s>We used multiple imputations with chained equations to impute missing data on covariates when calculating HR.</s><s>We used 10 imputed datasets and combined estimates and SE across studies using the Rubin rules <ref type="bibr" target="#b16">(16)</ref>.</s><s>To calculate the HR for death following a thrombotic or major bleeding event, follow-up of each patient was divided into time spent before and after a major bleeding or thrombotic event.</s><s>The association between these events and subsequent mortality was entered into a Cox-proportional hazards model as a time-updated categorical variable that enters the model on the day of the event (the methods in the Online Appendix).</s><s>HR therefore compare the hazard of death after an event to the hazard before an event (which includes the hazard in patients who do not have an event during follow-up).</s><s>We further broke each patient's follow-up after a thrombotic or major bleeding event into 3 time intervals (0 to 7, 8 to 30, and 31 to 365 days) based on similar analyses performed in other studies <ref type="bibr" target="#b17">(17)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>PATIENTS.</s><s>Of the 2,432 patients who underwent PCI, 2,386 (98.1%) were followed until death or 730 days (Online Figure <ref type="figure" target="#fig_5">1</ref>).</s><s>Only 9 patients in the DCS arm and 3 in the BMS arm were lost to follow-up before 2 years.</s><s>Patients were included based on pre-defined criteria of an increased bleeding risk, mainly age $75 years (64.3%),</s><s>prolonged oral anticoagulation (36.1%), renal failure (19.1%), planned major surgery (16.4%), hemoglobin &lt;11 g/l or recent transfusion (15.6%), and cancer in the previous 3 years (9.8%).</s><s>The DCS and BMS groups were well matched with regard to baseline characteristics (Online Table <ref type="table" target="#tab_2">2</ref>).</s></p><p><s>At 730 days, 78.8% of patients in the DCS group and 76.8% in the BMS group were receiving single antiplatelet therapy; 5.3% and 7.6%, respectively, had DAPT; 15.8% and 15.6%, respectively, were taking no antiplatelet drug; and 37.7% and 38.0%, respectively, were taking oral anticoagulants.</s><s>Details regarding antithrombotic treatment are given in Online Table <ref type="table" target="#tab_4">3</ref>.</s></p><p><s>PRIMARY OUTCOMES AT 2 YEARS.</s><s>We previously reported outcomes using a 390-day time point <ref type="bibr" target="#b0">(1)</ref>.</s></p><p><s>Garot et al.</s></p><p><s>To facilitate comparisons between the first and second follow-up years, time points of 365 and 730 days were used for 1 and 2 years in the present analysis.</s></p><p><s>Between 1 and 2 years, there were 53 new occurrences of a primary safety endpoint in 37 DCS patients and 44 in 29 BMS patients.</s><s>The primary safety outcomes at 2 years occurred more frequently in the BMS than in the DCS group (15.3% vs. 12.6%; HR: 0.80; 95% CI: 0.64 to 0.99; p ¼ 0.039) (Table <ref type="table" target="#tab_1">1</ref>, Central Illustration, Figure <ref type="figure" target="#fig_5">1</ref>).</s></p><p><s>Between 1 and 2 years, there were 24 new clinically driven target lesion revascularizations (the primary efficacy endpoint) in 20 patients of the DCS group and 43 in 29 patients of the BMS group.</s><s>Clinically driven target lesion revascularization was required at least once in 6.8% of DCS and 12.0% of BMS patients at 2 years (HR: 0.54; 95% CI: 0.41 to 0.72; p &lt; 0.0001) (Table <ref type="table" target="#tab_1">1</ref>, Central Illustration, Figure <ref type="figure" target="#fig_5">1</ref>).</s><s><ref type="table" target="#tab_1">1</ref>.</s><s>There were no significant differences in mortality between the DCS and BMS groups in either all-cause mortality (13.1% vs. 13.8%;</s><s>HR: 0.94; 95% CI: 0.75 to 1.17; p ¼ 0.57) or cardiac mortality (6.6% vs. 6.9%;</s><s>HR: 0.94; 95% CI: 0.69 to 1.28; p ¼ 0.69) (Table <ref type="table" target="#tab_1">1</ref>).</s><s>Between the first and second years of follow-up, 48 myocardial infarctions occurred (25 in 20 patients of the DCS group, and 23 in 14 patients of the BMS group) and 2 very late definite or probable stent thromboses (1 in the DCS group and 1 in the BMS group).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OTHER CLINICAL OUTCOMES. Other clinical outcomes are summarized in Table</head><p><s>The incidence of coronary thrombotic events from randomization to 2 years (defined as any myocardial infarction and/or definite or probable stent thrombosis) was significantly lower with DCS than with BMS (8.2% vs. 10.6%;</s><s>p ¼ 0.045) (Table <ref type="table" target="#tab_1">1</ref>).</s><s>Major bleeding over 2 years occurred at a similar rate in both DCS and BMS groups (8.9% vs. 9.2%; p ¼ 0.95) (Central Illustration).</s><s>Pre-specified subgroup comparisons for the primary efficacy and safety endpoints are shown in Online Figure <ref type="figure">2</ref>.</s><s>These analyses show a consistent treatment effect across most subgroups.</s><s>However, interaction testing suggested heterogeneity of treatment effect with regard to the primary safety endpoint according to whether or not the patient presented with an acute coronary syndrome, and with regard to the primary efficacy endpoint in patients with a CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score &gt;35.</s><s>Both of these subgroups had already been identified at the 1-year follow-up (1).</s></p><p><s>We identified 8 baseline and procedural characteristics correlated with major bleeding and primary safety endpoint events at 2 years: 4 were related to the safety endpoint only (congestive heart failure, multivessel disease, number of stents and stent type); 2 to bleeding events only (planned oral anticoagulation and raised plasma creatinine); and 2 to both (age &gt;75 years and low hemoglobin) (Table <ref type="table" target="#tab_2">2</ref>).</s><s>Of note, use of a BMS had a 33% relative increase in the hazard for safety endpoint events (p ¼ 0.04) compared with DCS after covariate adjustment.</s></p><p><s>The risks of all-cause death 1 year after a major bleed and 1 year after a coronary thrombotic event were 27.1% and 26.3%, respectively (Figure <ref type="figure">2</ref>).</s><s>Both show a similar pattern with very marked excess mortality risk within the first week after such eventsespecially for coronary thrombotic events-which then attenuates over time (Table <ref type="table" target="#tab_4">3</ref>).</s><s>A major bleed remains associated with a significant excess mortality risk during 31 to 365 days after the event (adjusted HR: 2.54; p &lt; 0.001).</s><s>These mortality patterns were no different for both DCS and BMS groups, though the former has a reduced risk of a coronary thrombotic event (Table <ref type="table" target="#tab_1">1</ref>).</s><s>The Kaplan-Meier time-to-event curves show the cumulative percentage of patients with the primary safety endpoint (a composite of cardiac death, myocardial infarction, or stent thrombosis) (A), the primary efficacy endpoint (clinically driven target-lesion revascularization) (B), major bleeding (C), and the 3 components of the safety endpoint (D to F). BMS ¼ bare-metal stent(s); DCS ¼ drug-coated stent(s); HBR ¼ high bleeding risk.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CENTRAL ILLUSTRATION HBR</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>For HBR patients receiving a 1-month course of DAPT, 2-year follow-up in the LEADERS FREE trial demonstrates, for both efficacy and safety, the sustained superiority of the BioFreedom polymer-free biolimus A9-coated stent (DCS) compared with a similar BMS.</s></p><p><s>In this patient population, both the risks of major bleeding and of a composite of cardiac death, myocardial infarction, or stent thrombosis were high.</s></p><p><s>Both types of events were associated with several baseline and procedure characteristics, and when 2 of the components of the primary safety endpoint (myocardial infarction and/or stent thrombosis) were analyzed for their associated post-event 1-year allcause mortality, this was high-26.3%-and</s><s>comparable to that observed after major bleeding (27.1%).</s></p><p><s>Encouragingly for the DCS, no "catch-up" of target lesion revascularization was observed beyond 1 year.</s><s>This is in keeping with studies of a polymer-free stent as well as a rapid-elution permanent polymer DES <ref type="bibr" target="#b18">(18,</ref><ref type="bibr" target="#b19">19)</ref> and different from what has been seen with first generation DES <ref type="bibr" target="#b20">(20)</ref>.</s><s>It is plausible that biolimus A9 is particularly well suited to rapid delivery into the vessel wall because of its marked lipophilicity <ref type="bibr" target="#b8">(9)</ref>.</s><s>The low incidence of very late stent thrombosis in both trial arms (&lt;0.1%) suggests that absence of any polymer on the DCS may contribute to its long-term safety despite the very short DAPT and compares favorably with stent thrombosis rates for polymercoated DES, especially in this high risk population <ref type="bibr" target="#b21">(21)</ref><ref type="bibr" target="#b22">(22)</ref><ref type="bibr" target="#b23">(23)</ref><ref type="bibr" target="#b24">(24)</ref><ref type="bibr" target="#b25">(25)</ref><ref type="bibr" target="#b26">(26)</ref>.</s></p><p><s>These data confirm the good long-term results of DCS observed in a previous study <ref type="bibr" target="#b9">(10)</ref>.</s><s>However, HBR patients continue to suffer a high incidence of adverse events beyond the first year, most likely due to advanced age, major comorbidities, and possibly because of only partial revascularization in some patients (multivessel disease was reported in 62% of patients, but multivessel index revascularization was done in only 22%) <ref type="bibr" target="#b0">(1)</ref>.</s><s>Two-year mortality was 13.1% for DCS versus 13.8% for BMS patients.</s><s>This is higher than observed in all-comer trials and again points to the impact of comorbid conditions <ref type="bibr" target="#b23">(23,</ref><ref type="bibr" target="#b26">(26)</ref><ref type="bibr" target="#b27">(27)</ref><ref type="bibr" target="#b28">(28)</ref><ref type="bibr" target="#b30">(29)</ref>.</s></p><p><s>The ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates) trial randomized  The Kaplan Meier time-to-event curves show the cumulative percentage of patients who reached the primary safety endpoint (left) and the primary efficacy endpoint (right) for the first time between 365 and 730 days.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1,606 patients considered uncertain DES candidates</head><p><s>to either a first-generation rapid-elution zotarolimus DES with a biocompatible permanent polymer or a thin-strut BMS <ref type="bibr" target="#b31">(30)</ref>.</s><s>Among these patients, 52% had HBR, and their median DAPT duration was 30 days.</s></p><p><s>The overall trial found better safety and efficacy for the DES, even more pronounced for HBR patients with substantial reductions in myocardial infarction and target vessel revascularization and a stent thrombosis rate of 2.6% versus 6.2% for DES and BMS, respectively <ref type="bibr" target="#b1">(2,</ref><ref type="bibr" target="#b31">30)</ref>.</s><s>Two other randomized trials evaluated this rapid-elution zotarolimus-eluting DES in low bleeding risk patients and concluded that a 3-month course of DAPT was as safe and effective as a prolonged course of DAPT, but both were somewhat underpowered <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b5">6)</ref>.</s><s>The larger DAPT trial enrolled 9,961 low to medium bleeding risk patients after implantation of several slow-eluting DES and an uneventful first 12 months' period and evaluated prolonged DAPT.</s><s>Rates of myocardial infarction and stent thrombosis were significantly lower with 30 than with 12 months' DAPT, but at the cost of an increase in bleeding <ref type="bibr" target="#b32">(31)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The recent NORSTENT (Norwegian Coronary Stent</head><p><s>Trial) randomized 9,013 patients to either a contemporary DES or a thin-strut BMS, and it found that with a 9-month DAPT course in both arms and after a 6-year follow-up, both stent types were equivalent for safety (cardiac death or myocardial infarction), whereas DES were superior in terms of need for repeat revascularization and a lower rate of stent thrombosis <ref type="bibr" target="#b33">(32)</ref>.</s><s>Because both the DAPT duration and the patients' risk profiles were very different from those of LEADERS FREE, we believe that both trials complement rather than contradict each other.</s><s>BMS design is unlikely to be a major factor, because the thin strut BMS used in NORSTENT were very similar to those used in ZEUS, where active stents were also both safer and more effective than BMS in HBR patients treated with a short course of DAPT <ref type="bibr" target="#b1">(2,</ref><ref type="bibr" target="#b31">30)</ref>.</s></p><p><s>Interest in shortening DAPT when needed is now considerable, and there are at least 9 randomized trials currently planned or ongoing to evaluate DAPT regimens of 3 months or less after coronary stenting.</s></p><p><s>Some use stents with rapid drug transfer to the vessel wall, a logical feature when very short DAPT appears desirable, and others use stents coated with either a permanent or biodegradable polymer that delivers the antiproliferative drug over several months.</s></p><p><s>Whether such strategies are safe remains to be demonstrated <ref type="bibr" target="#b34">(33)</ref>.</s></p><p><s>One important finding in our trial is that both bleeding and coronary thrombotic event rates</s></p><p><s>(myocardial infarction and/or stent thrombosis) are high and similar in HBR patients.</s><s>Although this balance has already been described for all-comer patients <ref type="bibr" target="#b35">(34)</ref>, both types of events are clearly more frequent in HBR patients.</s><s>In the present trial, 8.2% of patients suffered a coronary thrombotic event (myocardial infarction and/or stent thrombosis) and 8.9% suffered a major bleeding event at 2 years in the DCS group, whereas these events occurred in 10.6%</s></p><p><s>for thrombotic and 9.2% for bleeding events in the BMS group.</s><s>In the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients) registry that analyzed 4,190 patients after coronary stenting, the majority of whom were maintained on DAPT for at least 1 year, coronary thrombotic events occurred in 3.8% and major BARC bleeding (BARC 3 or 5) in 3.3% <ref type="bibr" target="#b35">(34)</ref><ref type="bibr" target="#b36">(35)</ref><ref type="bibr" target="#b37">(36)</ref><ref type="bibr" target="#b38">(37)</ref>.</s><s>This difference is again most probably due to the more advanced age and greater comorbidity of HBR patients, compared with an all-comer population.</s><s>Of interest is the fact that the ratio of thrombotic to bleeding events at 2 years was very similar in both trials (0.92 for the DCS arm and 1.15 for the BMS arm in LEADERS FREE, and 1.15 in PARIS).</s></p><p><s>The risk of ensuing mortality is also high, especially soon after the event.</s><s>Of note is the persistently high excess mortality out to 1 year after a major bleed.</s><s>at the price of an increased risk of major bleeding <ref type="bibr" target="#b36">(35,</ref><ref type="bibr" target="#b37">36)</ref>.</s><s>LEADERS FREE was designed to compare a new stent to a BMS using the accepted standard of 1 month DAPT in HBR patients, but the optimal duration of DAPT still remains to be determined in this high-risk population.</s></p><p><s>Among characteristics associated with either bleeding or the primary safety endpoint (</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>The safety and efficacy benefits of a polymer-free biolimus A9-eluting stent versus a BMS together with a short 1-month DAPT course were maintained during 2 years of follow-up.</s><s>The persistently high incidence of both bleeding and coronary thrombotic events in HBR patients needs wider recognition and deserves our full attention in future trials of antithrombotic therapy.</s></p><p><s>REPRINT REQUESTS AND CORRESPONDENCE: Dr. Philip Urban, Cardiology Department, Hôpital de la Tour, 1 Avenue J.D. Maillard, 1217 Geneva,</s></p><p><s>Switzerland.</s><s>E-mail: philip.urban@latour.ch.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>patients were to receive DAPT including both aspirin (75 to 250 mg once daily) and a P2Y 12 inhibitor (with clopidogrel preferred) for 30 days followed by a single antiplatelet agent thereafter (aspirin preferred).</s><s>Patients requiring a vitamin K antagonist could be treated either by triple therapy or a vitamin K antagonist plus clopidogrel only during the first 30 days.</s><s>Patients had follow-up visits at 30 and 365 days and were contacted either on site or by telephone at 60, 120, and 730 days.</s><s>Ischemia testing and angiographic evaluation during follow-up was left to the investigator's discretion.</s><s>STUDY DESIGN AND OVERSIGHT.</s><s>A total of 2,466 patients from 68 sites were randomized to receive either the BioFreedom DCS or the Gazelle BMS.</s><s>The study was sponsored by Biosensors Europe and conducted by the Cardiovascular European Research Center, an independent research organization paid by SEE PAGE 172 A B B R E V I A T I O N S A N D A C R O N Y M S BARC = Bleeding Academic Research Consortium BMS = bare-metal stents CI = confidence interval DAPT = dual antiplatelet therapy DCS = drug-coated stent(s) DES = drug-eluting stent(s) HBR = high bleeding risk HR = hazard ratio PCI = percutaneous coronary intervention Kingdom; s St. Thomas Hospital, London, United Kingdom; t Cardiovascular European Research Center, Massy, France; and the u Cardiovascular Department, Hôpital de la Tour, Geneva, Switzerland.</s><s>All financial support for the trial was provided by the sponsor, Biosensors Europe.</s><s>Dr. Pocock has received consulting fees from Biosensors.</s><s>Dr. Meredith has received consulting fees, proctor fees, and honoraria from Boston Scientific; and has received consulting fees and honoraria from Medtronic.</s><s>Dr. Abizaid has received research grants from Abbott Vascular, Medtronic, Elixir, and Riva.</s><s>Dr. Menown has received grants to his institution from Biosensors, Boston Scientific, Meril Life, and Orbus Neich; and has received conference sponsorship from Biosensors.Dr.</s><s>Christiansen has received grants to his institution from Biosensors.</s><s>Dr.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>HR for death were adjusted for correlates of thrombotic or major bleeding events.</s><s>Analyses were performed with Stata Software (version 14.1, Stata Corp., College Station, Texas) and SAS (version 9.3, SAS Institute, Cary, North Carolina), and all p values were calculated using 2-sided hypothesis tests.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Patients After Polymer-Free DCS: Primary Safety Endpoint, Primary Efficacy Endpoint, Major Bleeding, and Individual Components of the Primary Safety Endpoint Garot, P. et al.</s><s>J Am Coll Cardiol.</s><s>2017;69(2):162-71.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>These</head><label></label><figDesc><div><p><s>findings are similar to those of ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy Trial) (17), a trial focused on patients presenting with acute coronary syndrome, but the adjusted HR for mortality associated with major bleeding and thrombotic events were markedly</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>FIGURE 2 1 -</head><label>1</label><figDesc><div><p><s>FIGURE 2 1-Year Mortality Following a Major Bleed or a Coronary Thrombotic Event</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>Gregson has received consulting fees and research grants from Biosensors.</s><s>Drs.</s><s>Copt and Stroll are full-time employees of Biosensors.</s><s>Dr. Windhövel is a full-time employee of Cardiovascular European Research Center, the clinical research organization that ran the trial.</s><s>Ms. Greene has received consulting fees from Biosensors.</s><s>Dr. Urban has received consulting fees from Biosensors.</s><s>All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</s><s>Manuscript received September 15, 2016; revised manuscript received October 6, 2016, accepted October 7, 2016.</s></p></div></figDesc><table><row><cell>JACC VOL. 69, NO. 2, 2017</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 1</head><label>1</label><figDesc><div><p><s>Clinical Outcomes at 1 and 2 Years With a DCS or BMS</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>1 Year</cell><cell></cell><cell></cell><cell>2 Years</cell><cell></cell></row><row><cell></cell><cell>DCS</cell><cell>BMS</cell><cell></cell><cell>DCS</cell><cell>BMS</cell><cell></cell></row><row><cell></cell><cell>(n ¼ 1,221)</cell><cell>(n ¼ 1,211)</cell><cell>p Value</cell><cell>(n ¼ 1,221)</cell><cell>(n ¼ 1,211)</cell><cell>p Value</cell></row><row><cell>Primary safety endpoint: cardiac</cell><cell>110 (9.2)</cell><cell>151 (12.7)</cell><cell>0.006</cell><cell>147 (12.6)</cell><cell>180 (15.3)</cell><cell>0.039</cell></row><row><cell>death, MI, or stent thrombosis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Primary efficacy endpoint: clinically driven TLR</cell><cell>57 (4.9)</cell><cell>107 (9.3)</cell><cell>&lt;0.001</cell><cell>77 (6.8)</cell><cell>136 (12.0)</cell><cell>&lt;0.0001</cell></row><row><cell>Death</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>From any cause</cell><cell>91 (7.5)</cell><cell>105 (8.7)</cell><cell>0.27</cell><cell>156 (13.1)</cell><cell>164 (13.8)</cell><cell>0.57</cell></row><row><cell>From cardiac causes</cell><cell>49 (4.1)</cell><cell>61 (5.1)</cell><cell>0.23</cell><cell>76 (6.6)</cell><cell>80 (6.9)</cell><cell>0.69</cell></row><row><cell>MI*</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Any</cell><cell>70 (5.9)</cell><cell>103 (8.7)</cell><cell>0.008</cell><cell>90 (7.4)</cell><cell>117 (10.1)</cell><cell>0.04</cell></row><row><cell>Q-wave infarction</cell><cell>6 (0.5)</cell><cell>7 (0.6)</cell><cell>0.77</cell><cell>6 (0.5)</cell><cell>10 (0.9)</cell><cell>0.31</cell></row><row><cell>Non-Q-wave infarction</cell><cell>55 (4.7)</cell><cell>78 (6.7)</cell><cell>0.04</cell><cell>67 (5.8)</cell><cell>86 (7.4)</cell><cell>0.09</cell></row><row><cell>Undetermined type</cell><cell>10 (0.8)</cell><cell>26 (2.2)</cell><cell>0.007</cell><cell>18 (1.6)</cell><cell>31 (2.7)</cell><cell>0.06</cell></row><row><cell>Stent thrombosis*</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Definite or probable</cell><cell>24 (2.0)</cell><cell>26 (2.2)</cell><cell>0.75</cell><cell>25 (2.1)</cell><cell>27 (2.3)</cell><cell>0.76</cell></row><row><cell>Definite</cell><cell>16 (1.3)</cell><cell>17 (1.4)</cell><cell>0.84</cell><cell>17 (1.4)</cell><cell>17 (1.4)</cell><cell>0.98</cell></row><row><cell>Probable</cell><cell>8 (0.7)</cell><cell>9 (0.8)</cell><cell>0.80</cell><cell>8 (0.7)</cell><cell>10 (0.9)</cell><cell>0.63</cell></row><row><cell>Possible</cell><cell>25 (2.2)</cell><cell>26 (2.2)</cell><cell>0.85</cell><cell>36 (3.2)</cell><cell>35 (3.1)</cell><cell>0.95</cell></row><row><cell>Early definite or probable</cell><cell>12 (1.0)</cell><cell>15 (1.2)</cell><cell>0.55</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>(acute þ subacute)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Late definite or probable</cell><cell>13 (1.1)</cell><cell>11 (1.0)</cell><cell>0.70</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Very late definite or probable</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>1 (0.1)</cell><cell>1 (0.1)</cell><cell>0.99</cell></row><row><cell>Coronary thrombotic event* †</cell><cell>76 (6.4)</cell><cell>109 (9.3)</cell><cell>0.01</cell><cell>96 (8.2)</cell><cell>123 (10.6)</cell><cell>0.045</cell></row><row><cell>Bleeding* ‡</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>BARC 1-5</cell><cell>213 (17.9)</cell><cell>225 (19.1)</cell><cell>0.50</cell><cell>258 (22.0)</cell><cell>255 (22.3)</cell><cell>0.89</cell></row><row><cell>BARC 2-5</cell><cell>165 (13.9)</cell><cell>173 (14.8)</cell><cell>0.61</cell><cell>204 (17.4)</cell><cell>206 (17.9)</cell><cell>0.83</cell></row><row><cell>BARC 3-5</cell><cell>85 (7.2)</cell><cell>85 (7.3)</cell><cell>0.96</cell><cell>105 (8.9)</cell><cell>105 (9.2)</cell><cell>0.95</cell></row><row><cell>Revascularization</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Any TVR</cell><cell>65 (5.6)</cell><cell>119 (10.3)</cell><cell>&lt;0.001</cell><cell>91 (8.1)</cell><cell>151 (13.3)</cell><cell>&lt;0.0001</cell></row><row><cell>TVR by CABG</cell><cell>4 (0.3)</cell><cell>11 (1.0)</cell><cell>0.07</cell><cell>6 (0.5)</cell><cell>12 (1.1)</cell><cell>0.14</cell></row><row><cell>Any revascularization</cell><cell>94 (8.1)</cell><cell>134 (11.6)</cell><cell>0.003</cell><cell>129 (11.4)</cell><cell>180 (15.9)</cell><cell>0.001</cell></row></table><note><p><s>(11)es are n (%).Percentages are Kaplan-Meier estimates at 365 (1 year) and 730 days (2 years).*Subcategories of MI, stent thrombosis, or bleeding are not mutually exclusive, because patients could have &gt;1 subtype of these events during follow-up.†AnyMI</s><s>and/or definite or probable stent thrombosis.‡Bleeding was defined according to the BARC definitions.BARC type 0 indicates no bleeding, and BARC type 5 indicates fatal bleeding(11).</s><s>BARC ¼ Bleeding Academic Research Consortium; BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass graft; DCS ¼ drug-coated stent(s); MI ¼ myocardial infarction; TLR ¼ target-lesion revascularization; TVR ¼ target-vessel revascularization.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 2</head><label>2</label><figDesc><div><p><s>Multivariate Correlates of Primary Safety Endpoint and Landmark Analysis at 1 Year for the Primary Safety and Primary Efficacy Endpoints</s></p></div></figDesc><table><row><cell>Major Bleeding</cell><cell></cell><cell></cell></row><row><cell></cell><cell>HR (95% CI)</cell><cell>p Value</cell></row><row><cell>Primary safety endpoint*</cell><cell></cell><cell></cell></row><row><cell>Age &gt;75 yrs</cell><cell>1.56 (1.23-1.97)</cell><cell>&lt;0.001</cell></row><row><cell>Hemoglobin (per 1 mmol/l &lt;9)</cell><cell>1.32 (1.19-1.46)</cell><cell>&lt;0.001</cell></row><row><cell>Congestive heart failure at baseline</cell><cell>1.61 (1.23-2.11)</cell><cell>0.001</cell></row><row><cell>Multivessel disease at baseline †</cell><cell>1.66 (1.27-2.18)</cell><cell>&lt;0.001</cell></row><row><cell>Number of stents implanted</cell><cell>1.13 (1.04-1.23)</cell><cell>0.005</cell></row><row><cell>(per additional stent)</cell><cell></cell><cell></cell></row><row><cell>BMS</cell><cell>1.28 (1.03-1.59)</cell><cell>0.027</cell></row><row><cell>Major bleeding event ‡</cell><cell></cell><cell></cell></row><row><cell>Age &gt;75 yrs</cell><cell>1.52 (1.13-2.06)</cell><cell>0.006</cell></row><row><cell>Hemoglobin (per 1 mmol/l &lt;9)</cell><cell>1.73 (1.52-1.96)</cell><cell>&lt;0.001</cell></row><row><cell>Serum creatinine &gt;150 mmol/l</cell><cell>1.58 (1.10-2.27)</cell><cell>0.012</cell></row><row><cell>Planned OAC use post-PCI</cell><cell>2.01 (1.51-2.68)</cell><cell>&lt;0.001</cell></row></table><note><p><s>*Primary safety endpoint: composite of cardiac death, myocardial infarction, and definite/probable stent thrombosis.†Multivessel</s><s>disease includes patients with site-reported 2-or 3-vessel and/or left main disease.‡BARC</s><s>bleeding score 3 to 5. BMS ¼ bare-metal stent(s); CI ¼ confidence interval; HR ¼ hazard ratio; OAC ¼ oral anticoagulants; PCI ¼ percutaneous coronary intervention.FIGURE 1</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>),</cell></row></table><note><p><s>(34,37)ding, the need for long-term oral anticoagulation should always be carefully reassessed after PCI(40).Renal insufficiency was correlated only with bleeding in our series, but it has also been reported as a predictor of thrombotic complications by others(34,37).</s><s>It could either be that its thrombotic risk is of comparatively lesser importance for HBR patients who by definition often have other comorbid conditions, or that patients with the most severe renal dysfunction are already captured by their associated anemia.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>TABLE 3 1</head><label>3</label><figDesc><div><p><s>-Year Mortality Following a Major Bleed or Coronary Thrombotic Event</s></p></div></figDesc><table><row><cell>JACC VOL. 69, NO. 2, 2017</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Rate</cell><cell></cell></row><row><cell></cell><cell>Patients</cell><cell></cell><cell>Person-Time</cell><cell>(per Person-Year</cell><cell>Adjusted HR Versus No</cell></row><row><cell></cell><cell>With Event</cell><cell>Deaths</cell><cell>at Risk (yrs)</cell><cell>at Risk)</cell><cell>Event (95% CI)</cell></row><row><cell>First year after event</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Thrombotic event</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No event or before event</cell><cell>2,432</cell><cell>256</cell><cell>4,137.3</cell><cell>0.06</cell><cell>1.00 (reference)</cell></row><row><cell>0-365 days</cell><cell>219</cell><cell>64</cell><cell>257.3</cell><cell>0.25</cell><cell>4.43 (3.24-6.04)</cell></row><row><cell>Major bleeding</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No event or before event</cell><cell>2,432</cell><cell>255</cell><cell>4,153.5</cell><cell>0.06</cell><cell>1.00 (reference)</cell></row><row><cell>0-365 days</cell><cell>210</cell><cell>65</cell><cell>241.1</cell><cell>0.27</cell><cell>3.43 (2.49 to 4.74)</cell></row><row><cell>Time since event</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Thrombotic event</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No event or before event</cell><cell>2,432</cell><cell>256</cell><cell>4,137.3</cell><cell>0.06</cell><cell>1.00 (reference)</cell></row><row><cell>0-7 days</cell><cell>219</cell><cell>24</cell><cell>3.9</cell><cell>6.22</cell><cell>77.96 (49.29-123.30)</cell></row><row><cell>8-30 days</cell><cell>195</cell><cell>11</cell><cell>11.8</cell><cell>0.93</cell><cell>11.51 (6.19-21.40)</cell></row><row><cell>31-365 days</cell><cell>183</cell><cell>29</cell><cell>241.6</cell><cell>0.12</cell><cell>1.53 (0.93-2.53)</cell></row><row><cell>Major bleeding</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No event or before event</cell><cell>2,432</cell><cell>255</cell><cell>4,153.5</cell><cell>0.06</cell><cell>1.00 (reference)</cell></row><row><cell>0-7 days</cell><cell>210</cell><cell>16</cell><cell>3.8</cell><cell>4.2</cell><cell>36.11 (20.82-62.64)</cell></row><row><cell>8-30 days</cell><cell>192</cell><cell>3</cell><cell>11.9</cell><cell>0.25</cell><cell>2.41 (0.76-7.65)</cell></row><row><cell>31-365 days</cell><cell>186</cell><cell>46</cell><cell>225.4</cell><cell>0.2</cell><cell>2.36 (1.60-3.48)</cell></row></table><note><p><s>Abbreviations as in Table2.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J A C C V O L . 6 9 , N O . 2 , 2 0 1 7 2-Year Outcomes of HBR Patients After Polymer-Free DCS J A N U A R Y 1 7 , 2 0 1 7 : 1 6 2 -7 1</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J A N U A R Y 1 7 , 2 0 1 7 : 1 6 2 -7 12-Year Outcomes of HBR Patients After Polymer-Free DCS</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Polymer-free drugcoated coronary stents in patients at high bleeding risk</title>
		<author>
			<persName><forename type="first">P</forename><surname>Urban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Meredith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abizaid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">for the LEADERS FREE Investigators</title>
				<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="2038" to="2047" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">for the ZEUS Investigators. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ariotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Adamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Costa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol Intv</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="426" to="436" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rizvi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Newman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">for the SPIRIT IV Investigators</title>
				<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="1663" to="1674" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prasugrel versus clopidogrel in patients with acute coronary syndromes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Wiviott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mccabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">for the TRITON-TIMI 38 Investigators</title>
				<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="2001" to="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">for the RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Shin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1340" to="1348" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">for the OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Feres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abizaid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="2510" to="2522" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">ACC/ AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bittl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1082" to="1115" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">ESC/ EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Windecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Alfonso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2541" to="2619" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Polymer-free biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymercoated sirolimus-eluting cypher stent in a porcine model</title>
		<author>
			<persName><forename type="first">N</forename><surname>Tada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Virmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Grant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="174" to="183" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Polymer-free biolimus A9-coated stents in the treatment of de novo coronary lesions: 4-and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abizaid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">for the BioFreedom FIM Clinical Trial Investigators</title>
				<imprint>
			<publisher>multicenter</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">BioFreedom FIM clinical trial</title>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol Intv</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="51" to="64" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Rationale and design of the LEADERS FREE trial: a randomized double-blind comparison of the Bio-Freedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Urban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abizaid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chevalier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="704" to="709" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="2736" to="2747" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Third universal definition of myocardial infarction</title>
		<author>
			<persName><forename type="first">K</forename><surname>Thygesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Alpert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Jaffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="2020" to="2035" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Cutlip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Windecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="2344" to="2351" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A proportional hazards model for the subdistribution of a competing risk</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Fine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Gray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="496" to="509" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Inference and missing data</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Rubin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrika</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="581" to="592" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pocock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Stone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1457" to="1466" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Iijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mehilli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol Intv</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="291" to="299" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">for the ISAR-TEST-2 Investigators. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kastrati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tiroch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="2536" to="2543" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Fiveyear clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Räber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wohlwend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wigger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="2819" to="2828" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">for the SORT OUT IV Investigators. Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">O</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thayssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Christiansen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="751" to="762" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Comparison of zotarolimus-eluting and everolimuseluting coronary stents</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Serruys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Silber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Garg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="136" to="146" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymerbased sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Serruys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Farooq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kalesan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol Intv</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="777" to="789" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Clinical events and patient-reported chest pain in allcomers treated with Resolute integrity and Promus element stents: 2-year follow-up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II)</title>
		<author>
			<persName><forename type="first">H</forename><surname>Sen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Löwik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol Intv</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="889" to="899" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">for the BASKET-PROVE II Study Group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kostent-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galatius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jeger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="74" to="81" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Biolimuseluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Räber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kelbaek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Taniwaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">for the COMFORTABLE AMI Trial Investigators</title>
				<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="355" to="364" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in realworld patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tandjung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Lam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="2406" to="2416" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">for the BASKET-PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galatius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Erne</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="2310" to="2319" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Comparison of coronary bypass surgery with drugeluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kappetein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Mack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2125" to="2134" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates</title>
		<author>
			<persName><forename type="first">M</forename><surname>Valgimigli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patialiakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thury</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">for the ZEUS Investigators</title>
				<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="805" to="815" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">for the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents</title>
		<author>
			<persName><forename type="first">L</forename><surname>Mauri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Yeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="2155" to="2166" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">for the NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Bønaa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mannsverk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wiseth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1242" to="1252" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Silber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kirtane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Belardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1949" to="1956" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS</title>
		<author>
			<persName><forename type="first">U</forename><surname>Baber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Giustino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="2224" to="2234" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Incidence, predictors, and impact of postdischarge bleeding after percutaneous coronary intervention</title>
		<author>
			<persName><forename type="first">P</forename><surname>Généreux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Giustino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Witzenbichler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1036" to="1045" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">for the ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicenter registry study</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Witzenbichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Weisz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="614" to="623" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Time-dependent associations between actionable bleeding, coronary thrombotic events, and mortality following percutaneous coronary intervention: results from the PARIS Registry</title>
		<author>
			<persName><forename type="first">U</forename><surname>Baber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dangas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chandrasekhar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol Intv</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1349" to="1357" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents</title>
		<author>
			<persName><forename type="first">T</forename><surname>Pilgrim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vetterli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kalesan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="202" to="210" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">A risk score to predict bleeding in patients with acute coronary syndromes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pocock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nikolsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="2556" to="2566" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rubboli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Kovacic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="981" to="987" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">KEY WORDS bare-metal stent, bleeding, drug-coated stent, dual antiplatelet therapy, thrombosis APPENDIX For supplemental material as well as tables and figures</title>
		<imprint/>
	</monogr>
	<note>please see the online version of this paper</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
